Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.1
4.3
Journals
Pharmaceuticals
Special Issues
Therapeutic Agents for the Treatment of Tumors in the CNS
share announcement

Therapeutic Agents for the Treatment of Tumors in the CNS

A special issue of Pharmaceuticals (ISSN 1424-8247).

Deadline for manuscript submissions: 25 October 2024 | Viewed by 4370

Special Issue Editors

Dr. Gautham Gampa

E-Mail Website
Guest Editor
1. Department of Pharmaceutics, University of Minnesota Twin Cities, MN, USA
2. Genentech Inc., San Francisco, CA, USA
Interests: CNS drug delivery; oncology; pharmacokinetics/pharmacodynamics (PK/PD)
Dr. Sani H. Kizilbash

E-Mail Website
Guest Editor
Mayo Clinic, Rochester, MN, United States
Interests: gliomas; clinical trials; CNS malignancies
Dr. Shannon P. Fortin Ensign

E-Mail Website
Guest Editor
Mayo Clinic, Phoenix, AZ, USA
Interests: gliomas; brain metastases; translational research

Special Issue Information

Dear Colleagues,

This Special Issue aims to create a platform for the exchange of ideas and findings related to treatments for tumors in the central nervous system (CNS). The current shortage of disease-modifying treatments for patients with both primary and metastatic brain tumors represents one of the most significant unmet needs of our time. Our ability to effectively tap into otherwise-promising anti-cancer therapies is challenged by the blood–brain barrier, which severely restricts the entry of systemic/orally delivered therapeutic agents into the brain. We seek innovative thoughts, research, and approaches to tackling critical questions relevant to the treatment of debilitating brain tumors.

We welcome contributions at the forefront of basic and translational neuro-oncology with potential to improve the diagnosis and treatment of tumors in the brain. This Special Issue aims to highlight the latest advances in treatments with transformative potential in neuro-oncology from experts in relevant fields such as pharmaceutical sciences, neuroscience, pharmacology, medical oncology, drug delivery, and clinical neuro-surgery. Along with original research articles, we encourage authors to submit comprehensive up-to-date reviews that detail the current status of these treatments and that provide perspectives or future directions. We aim to help the scientific community in finding better treatment options for patients afflicted with devastating CNS tumors.

Dr. Gautham Gampa
Dr. Sani H. Kizilbash
Dr. Shannon P. Fortin Ensign 
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • primary brain tumors
  • glioblastoma
  • brain metastases (BMs)
  • neuro-oncology
  • blood–brain barrier (BBB)
  • drug delivery
  • preclinical PK/PD
  • molecularly targeted agents
  • immunotherapy
  • new modalities

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

16 pages, 5455 KiB  
Article
Fatty Acid Amides Suppress Proliferation via Cannabinoid Receptors and Promote the Apoptosis of C6 Glioma Cells in Association with Akt Signaling Pathway Inhibition
by Nágila Monteiro da Silva, Izabella Carla Silva Lopes, Adan Jesus Galué-Parra, Irlon Maciel Ferreira, Chubert Bernardo Castro de Sena, Edilene Oliveira da Silva, Barbarella de Matos Macchi, Fábio Rodrigues de Oliveira and José Luiz Martins do Nascimento
Pharmaceuticals 2024, 17(7), 873; https://doi.org/10.3390/ph17070873 - 2 Jul 2024
Viewed by 445
Abstract
A glioma is a type of tumor that acts on the Central Nervous System (CNS) in a highly aggressive manner. Gliomas can occasionally be inaccurately diagnosed and treatments have low efficacy, meaning that patients exhibit a survival of less than one year after [...] Read more.
A glioma is a type of tumor that acts on the Central Nervous System (CNS) in a highly aggressive manner. Gliomas can occasionally be inaccurately diagnosed and treatments have low efficacy, meaning that patients exhibit a survival of less than one year after diagnosis. Due to factors such as intratumoral cell variability, inefficient chemotherapy drugs, adaptive resistance development to drugs and tumor recurrence after resection, the search continues for new drugs that can inhibit glioma cell growth. As such, analogues of endocannabinoids, such as fatty acid amides (FAAs), represent interesting alternatives for inhibiting tumor growth, since FAAs can modulate several metabolic pathways linked to cancer and, thus, may hold potential for managing glioblastoma. The aim of this study was to investigate the in vitro effects of two fatty ethanolamides (FAA1 and FAA2), synthetized via direct amidation from andiroba oil (Carapa guianensis Aublet), on C6 glioma cells. FAA1 and FAA2 reduced C6 cell viability, proliferation and migratory potential in a dose-dependent manner and were not toxic to normal retina glial cells. Both FAAs caused apoptotic cell death through the loss of mitochondrial integrity (ΔΨm), probably by activating cannabinoid receptors, and inhibiting the PI3K/Akt pathway. In conclusion, FAAs derived from natural products may have the potential to treat glioma-type brain cancer. Full article
(This article belongs to the Special Issue Therapeutic Agents for the Treatment of Tumors in the CNS)
►▼ Show Figures

Figure 1

Review

Jump to: Research

25 pages, 964 KiB  
Review
Current Status and Challenges of Oncolytic Virotherapy for the Treatment of Glioblastoma
by Mason J. Webb, Ugur Sener and Richard G. Vile
Pharmaceuticals 2023, 16(6), 793; https://doi.org/10.3390/ph16060793 - 26 May 2023
Cited by 7 | Viewed by 3040
Abstract
Despite decades of research and numerous clinical trials, the prognosis of patients diagnosed with glioblastoma (GBM) remains dire with median observed survival at 8 months. There is a critical need for novel treatments for GBM, which is the most common malignant primary brain [...] Read more.
Despite decades of research and numerous clinical trials, the prognosis of patients diagnosed with glioblastoma (GBM) remains dire with median observed survival at 8 months. There is a critical need for novel treatments for GBM, which is the most common malignant primary brain tumor. Major advances in cancer therapeutics such as immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapy have not yet led to improved outcomes for GBM. Conventional therapy of surgery followed by chemoradiation with or without tumor treating fields remains the standard of care. One of the many approaches to GBM therapy currently being explored is viral therapies. These typically work by selectively lysing target neoplastic cells, called oncolysis, or by the targeted delivery of a therapeutic transgene via a viral vector. In this review, we discuss the underlying mechanisms of action and describe both recent and current human clinical trials using these viruses with an emphasis on promising viral therapeutics that may ultimately break the field’s current stagnant paradigm. Full article
(This article belongs to the Special Issue Therapeutic Agents for the Treatment of Tumors in the CNS)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop